Phase 1 Multiple Ascending Dose Study of BMS-907351 (XL184) Monotherapy in Japanese Subjects With Advanced or Metastatic Solid Tumors.
Latest Information Update: 08 Aug 2010
Price :
$35 *
At a glance
- Drugs Cabozantinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 26 Jul 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
- 26 Jul 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 22 Jun 2010 Planned number of patients changed from 18 to 30 as reported by ClinicalTrials.gov.